Lenvatinib/lenvatinib: Characteristics and applications of third-generation targeted antitumor drugs

Lenvatinib is an advanced targeted therapy drug that, unlike traditional chemotherapy, can precisely attack specific molecular targets that cause cancer to grow and spread. As a third-generation anti-tumor targeted drug, lenvatinib prevents abnormal cell growth and reproduction by inhibiting the activity of tyrosine kinases. This tyrosine kinase is a key protein that promotes cell division and growth.

Lenvatinib belongs to the class of small molecule drugs, which effectively combats tumor progression by blocking the phosphorylation and activation processes of a variety of tyrosine kinases involved in tumor cell proliferation and neovascularization. This drug has shown significant therapeutic effects in different cancer types, especially in areas such as renal cell carcinoma, differentiated thyroid cancer, endometrial cancer, and hepatocellular carcinoma, where it has become an effective treatment option. At the same time, the toxicity profile of lenvatinib is relatively easy to control, making it better tolerated by patients during treatment.

As a new multi-kinase inhibitor, lenvatinib mainly exerts its anti-tumor effects by inhibiting the vascular endothelial growth factor receptor family (VEGFR 1-3), fibroblast growth factor receptor family (FGF R1-4), platelet-derived growth factor receptor-α (PDGFRα), tyrosine kinase receptor (KIT) and receptor rearranged during transfection (RET). Although lenvatinib may cause some side effects during treatment, such as hypertension, proteinuria, fatigue, and diarrhea, these side effects are mainly related to the anti-angiogenic effects of the drug and are generally predictable and manageable. If the patient experiences any discomfort or abnormal symptoms during medication, he or she should inform the doctor immediately so that the treatment plan can be adjusted in a timely manner.